Jun 16, 2020 · SAN DIEGO and Osaka, Japan, June 16, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline.

4 days ago · Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

5 days ago · About the Collaboration with Takeda In 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration to develop and commercialize compounds in depression and schizophrenia, including an exclusive license to both osavampator and NBI-1070770, which are being studied for the treatment of major depressive disorder, as well as a ...

4 days ago · Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement ...

3 days ago · On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...

4 days ago · The news comes amid an amended contract between Neurocrine and Takeda. The partners first entered into a neuroscience-focused pact in 2020 to advance a handful of the Japanese pharma’s pipeline assets for psychiatric indications, including schizophrenia, anhedonia and treatment-resistant depression. Neurocrine made a $120 million upfront ...

4 days ago · Neurocrine and Takeda, which is headquartered in Osaka, Japan, entered an agreement to develop and commercialize compounds for treatment of depression and schizophrenia in 2020.

5 days ago · Neurocrine Biosciences announced it has amended its agreement with Takeda to develop and commercialize osavampator. Under the amended agreement, Neurocrine will obtain exclusive rights for all ...

Apr 23, 2024 · Neurocrine Biosciences has nabbed a phase 2 win, with its investigational med in-licensed from Takeda significantly reducing depression severity among adults with major depressive disorder who...

Apr 23, 2024 · Neurocrine Biosciences, a drugmaker focused on the brain and nervous system, said Tuesday that one of its experimental medicines succeeded in a clinical trial evaluating it as a treatment for major depression.